SOP Guide for Pharma

Quality Assurance: SOP for Documentation of Change Control Processes – V 2.0

Quality Assurance: SOP for Documentation of Change Control Processes – V 2.0

Standard Operating Procedure for Documentation of Change Control Processes


Department Quality Assurance
SOP No. SOP/QA/190/2025
Supersedes SOP/QA/190/2022
Page No. Page 1 of 12
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To define a systematic approach for initiating, reviewing, implementing, and documenting changes to processes, procedures, materials, equipment, or documents that may impact the quality or compliance of sterile injectable products.

2. Scope

This SOP applies to all planned and unplanned changes at the sterile injectable manufacturing facility including

changes in equipment, facilities, standard operating procedures, raw materials, packaging materials, analytical methods, validation protocols, or production processes.

3. Responsibilities

  • Initiator: Identifies and proposes the change.
  • Department Head: Reviews feasibility and need for change.
  • Quality Assurance: Coordinates the change control process, conducts risk assessment, and ensures compliance with regulatory and GMP requirements.
  • Quality Control, Validation, Engineering, Regulatory: Support departments for assessment, implementation, and impact evaluation.
  • Change Control Committee (CCC): Final approval of major changes.

4. Accountability

The Head of Quality Assurance is accountable for ensuring that changes are properly evaluated, documented, reviewed, and implemented in compliance with applicable regulatory standards and internal policies.

5. Procedure

5.1 Change Initiation

  1. The concerned department raises a Change Control Form (Annexure-1) with details such as:
    • Type of change (Major/Minor)
    • Description of change
    • Justification
    • Documents or areas impacted
  2. QA assigns a unique Change Control Number (CCN) in the format CCN/YYYY/XXX.
  3. The initiator fills the preliminary details and submits to QA for evaluation.

5.2 Risk Assessment

  1. QA organizes a cross-functional meeting with all impacted departments.
  2. Risk assessment is conducted using tools like FMEA or risk matrix to evaluate:
    • Impact on product quality
    • Regulatory implications
    • Impact on validation and qualification status
    • Impact on documentation, SOPs, and training
  3. Risk level is categorized as Low, Medium, or High and documented in Annexure-2.

5.3 Change Classification

  1. Changes are categorized as:
    • Minor: No impact on product quality or regulatory filing. Example: typo correction in SOP.
    • Major: Impact on validation, product quality, regulatory dossier. Example: new equipment, formula change.
  2. Major changes require Change Control Committee (CCC) approval.

5.4 Change Implementation Plan

  1. QA prepares an implementation plan including:
    • Responsibility matrix
    • Timelines
    • Documents to be updated
    • Qualification/validation required
  2. Training is imparted if procedures are modified.
  3. All changes are implemented according to approved plan with proper documentation.

5.5 Verification and Closure

  1. Post-implementation, QA verifies:
    • All impacted SOPs, batch records, logbooks are revised
    • Validations are successfully completed
    • Training records are in place
  2. QA signs the Change Control Closure Report (Annexure-3).
  3. All documentation is archived and retained as per document retention policy.

6. Abbreviations

  • CCN: Change Control Number
  • CCC: Change Control Committee
  • QA: Quality Assurance
  • QC: Quality Control
  • SOP: Standard Operating Procedure
  • FMEA: Failure Modes and Effects Analysis

7. Documents

  1. Change Control Form – Annexure-1
  2. Risk Assessment Form – Annexure-2
  3. Change Control Closure Report – Annexure-3

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – Current Good Manufacturing Practice
  • EU GMP Chapter 1 – Pharmaceutical Quality System
  • WHO TRS 981 Annex 3

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QA Executive QA Manager Head QA
Department Quality Assurance Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Change Control Form

CCN CCN/2025/032
Initiator Ravi Kumar
Change Description Upgrade of visual inspection equipment
Justification Improved defect detection capability

Annexure-2: Risk Assessment Summary

Risk Area Impact Probability Risk Level
Product Quality Moderate Low Medium
Validation High Medium High

Annexure-3: Change Control Closure

CCN CCN/2025/032
Implemented On 21/06/2025
Closed By QA Manager
Closure Date 22/06/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
10/04/2022 1.0 Initial version issued New SOP Head QA
24/06/2025 2.0 Incorporated detailed risk evaluation and CCC references Annual Review Head QA
Exit mobile version